The first U.S. commercial cases have been completed with the Abbott (NYSE: ABT)+
Aveir dual-chamber leadless pacemaker technology.

An advanced closed-loop anesthesia delivery system that monitors brain state to tailor propofol dose and achieve exactly the desired level of unconsciousness could reduce post-op side effects.